Sponsored Links
| ASCO 2011: New Analysis Further Reinforces Erbitux Benefits For Patients With Metastatic Bowel Cancer |
 |
 |
 |
| Medical News - GastroIntestinal and Gastroenterology | |||
|
At the start of this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Merck Serono, a division of Merck KGaA, Darmstadt, Germany, presented a retrospective analysis of the CRYSTAL and OPUS trials which demonstrated that, by treating a specific population of metastatic bowel cancer patients (KRAS wild-type) with Erbitux® (cetuximab) in combination with sta... Read more: GastroIntestinal / Gastroenterology News From Medical News Today
|